Introduction
============

In the last decade, polyomavirus BK-associated nephropathy (PyVAN) has emerged as significant cause of premature kidney transplant (KT) failure in many transplant centers around the world [@b1]--[@b3]. PyVAN rates range from 1% to 10%, and progressive graft failure is seen in more than half of the cases [@b4]--[@b6]. In recent analyses of large US databases covering approximately 40 000 KT patients during the period 2003--2006, treatment for BKV was reported in 6.6% during the first 5 years posttransplant and the adjusted risk of graft loss was at least twofold higher compared to unaffected patients [@b7],[@b8]. In the absence of specific antiviral therapy, current treatment relies on reducing immunosuppression using rising plasma BKV loads as a surrogate marker of disease [@b9]--[@b12]. This approach can result in good clinical outcomes when performed early posttransplant [@b13],[@b14]. Accordingly, plasma BKV loads are currently recommended for screening and monitoring KT patients with presumptive and proven PyVAN [@b5],[@b15],[@b16]. Despite growing consensus about screening, the risk factors for BKV viremia and nephropathy are not well defined [@b16]. Most likely, nonmodifiable donor and recipient determinants synergize with potentially modulating factors such as immunosuppression [@b17]. In the face of the unchanged seroepidemiology of BKV infection [@b9],[@b18], increasing use of tacrolimus (Tac) compared to cyclosporine (CsA) has been discussed as a potential factor [@b19]. However, while some studies reported a higher risk of BKV viruria, viremia and/or nephropathy in Tac-treated patients compared to CsA-treated patients [@b2],[@b20], other studies were unable to identify such relation [@b11],[@b21]. To investigate the impact of the calcineurin inhibitor (CNI) directly, we examined BKV viruria and viremia in more than 600 *de novo* kidney transplant patients randomized 1:1 to Tac or CsA as part of the [D]{.ul}iabetes [I]{.ul}ncidence after [RE]{.ul}nal Transplantation: [C]{.ul}yclosporine C2 monitoring versus [T]{.ul}acrolimus (DIRECT) study [@b22].

Methods
=======

Patients
--------

The DIRECT study is a prospective 6-month, open-label multicenter study with a follow-up visit at month 12 randomizing *de novo* KT patients to CsA or Tac. The study methodology has been described elsewhere [@b22]. In brief, *de novo* renal transplant recipients aged 18--70 years (deceased, living-related or living-unrelated donor) were randomized 1:1 to CsA or Tac. Randomization was automated and investigators were notified via an interactive voice response system. The coprimary endpoints of this study were new onset diabetes or impaired fasting glucose, and biopsy-proven acute rejection, graft loss or death [@b22], and BKV replication was a secondary endpoint (see NCT00171496 at <http://ClinicalTrials.gov>). The study was performed in 59 transplant centers in 15 countries during October 2003 to March 2005 (see the Appendix). CsA (Neoral®, Novartis Pharma AG, Basel, Switzerland) dose was adjusted targeting C2 ranges: 1400--1800 ng/mL during month 1, 1200--1600 ng/mL during months 2--3 and 800--1200 ng/mL during months 4--6. Tac (Prograf®, Astellas Pharma, Tokyo, Japan) dosing was based on C0 targets: 10--15 ng/mL during months 1--3 and 5--10 ng/mL during months 4--6. All patients received mycophenolic acid (MPA) in the form of mycophenolate mofetil (MMF, Cellcept®, Roche Pharmaceuticals, Basel, Switzerland) or enteric-coated mycophenolate sodium (EC-MPS, myfortic®, Novartis Pharma AG) administered according to local practice, with corticosteroids (intravenous methylprednisolone 500 mg followed by oral prednisone tapered from 100--200 mg/day on day 1 to 5--10 mg/day from month 3 onward). Induction therapy consisted of two 20 mg doses of basiliximab (Simulect®, Novartis Pharma AG) given on days 0 and 4.

Virological analysis
--------------------

Collection of urine and EDTA blood samples was scheduled at baseline (i.e. pretransplantation or on the day of transplantation) and at months 1, 2, 3, 6 and 12. All samples were frozen at −20°C until analyzed by a quantitative real-time polymerase chain reaction [@b23] in the Division Infection Diagnostics, University of Basel (STS217 ISO/IEC-17025). BKV viruria was defined as detecting BKV DNA above a diagnostic threshold of 2500 copies/mL, high-level BKV viruria as urine DNA loads of \>7 log~10~ copies/mL [@b5]. BKV viremia was defined as plasma BKV loads above the lower diagnostic limit of detection of 1000 copies/mL, high-level BKV viremia as plasma BKV loads of \>4 log~10~ copies/mL [@b5].

Statistical analysis
--------------------

Kaplan--Meier analyses were applied to determine cumulative incidences omitting patients with detectable BKV at baseline. Standard summary statistics were determined for numerical results. Missing samples were not imputed and not included in the analyses. In univariate analyses, we investigated potential determinants of BKV replication including age, gender, race, preexisting diabetes, HLA-mismatches, cold ischemia time, delayed graft function, donor status (living versus deceased), type of dialysis prior to transplantation, CMV status of donor and recipient, recipients' hepatitis C virus (HCV) status and CNI. Multivariate logistic regression modeling was performed to investigate risk factors of BKV viruria and viremia at months 6 and 12. Odds ratios (OR) were calculated for 10 years of age and for 1 g of cumulative steroid dose, respectively. Cumulative steroid doses \>10 g were censored at 10 g to avoid undue influence of exceptional outliers. Binary variables were used for CNI type (CsA vs. Tac), gender (male vs. female), race (white vs. nonwhite), history of diabetes mellitus (yes vs. no), sum of HLA mismatches at loci A, B and DR (\>4 vs. ≤ 4) and delayed graft function (yes vs. no). In sensitivity analyses, BKV samples were omitted from analysis if they were acquired after discontinuation of the study medication. All p-values were two-tailed and considered significant at \<0.05. Analyses were performed using SAS statistical software version 8.2 (SAS Institute, Cary, NC, USA).

Results
=======

A total of 3213 urine and 3531 plasma samples were obtained from 682 patients at the scheduled time points for BKV DNA testing. No posttransplant sample had been collected in 39 patients, and only one sample in 14 patients, together 53 patients excluded from further analysis. Thus, the BKV study population consisted of 629 kidney transplant recipients (92.2%) for whom a total of 3156 urine (98.2%) and 3465 plasma samples (98.1%) were obtained from at least two visits between months 1 and 6 posttransplant.

At baseline, BKV viruria was detected in 19 (5.0%) of 378 patients with residual urine production. None of these developed viremia, and only 8 remained viruric posttransplant at a low level of less than 5 log~10~ copies/mL. Baseline BKV viremia was found in 3 (0.5%) of 609 patients, but none had detectable viruria or viremia posttransplant. Kaplan--Meier estimates showed that the incidence of new onset BKV viruria and viremia at month 12 increased to 39.5% (95% CI 35.4%, 43.5%) and 23.9% (95% CI 20.4%, 27.3%), respectively ([Figure 1](#fig01){ref-type="fig"}A). Comparing different time points posttransplant, the highest rates of viruria and viremia were observed at month 6 (25.4% and 13.7%, respectively) which then decreased at month 12 (20.3% and 8.6%, respectively) ([Figure 1](#fig01){ref-type="fig"}B). Median urine BKV loads increased from 6.1 log~10~ copies/mL at month 1 to 7.4 log~10~ copies/mL at month 3 before declining to 6.0 log~10~ copies/mL at month 12 ([Figure 1](#fig01){ref-type="fig"}C). At that time point, one fourth of the samples (75th percentile) had very high urine viral loads above 8 log~10~ copies/mL. Plasma BKV loads increased from a median 3.8 log~10~ copies/mL at month 1 to 4.7 log~10~ copies/mL at month 12 ([Figure 1](#fig01){ref-type="fig"}D). Biopsy-proven acute rejection episodes were more frequent in patients with BKV viremia at month 6 (13.0% vs. 6.1%, p = 0.030) while no statistically significant association was found for viruria. The estimated glomerular filtration rate was not different for patients with or without viruria, but at month 12, viremic patients had a significantly impaired function compared to those without viremia (median GFR 60.4 mL/min \[25th percentile 45.6, 75th percentile 78.2\] vs. 65.7 mL/min \[25th percentile 53.1, 75th percentile 83.5\]; p = 0.032).
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Patients randomized to either CNI arm were found to have similar baseline characteristics, including recipient male gender, white race, mean age, history of diabetes, delayed graft function, living donor and mean HLA mismatch ([Table 1A](#tbl1){ref-type="table"}). BKV viruria rates increased up to month 3 without significant differences between CsA- and Tac-randomized patients, but there was a trend toward less viruria among CsA-treated patients at month 12 ([Figure 2](#fig02){ref-type="fig"}A). At month 6, fewer patients in the CsA-treatment arm had high-level viruria of \>7 log~10~ copies/mL compared to Tac-treated patients (p = 0.058) reaching statistically significance at month 12 (p = 0.001) ([Figure 2](#fig02){ref-type="fig"}B). Of note, median urine BKV loads were sevenfold lower (0.8 log~10~ copies/mL) in CsA- than in Tac-randomized patients at month 6 (p = 0.050) and approximately 30-fold lower (1.5 log~10~ copies/mL) at month 12 (p = 0.007; [Figure 2](#fig02){ref-type="fig"}C).

###### 

Demographic and baseline determinants in patients with or without BK viruria at months 6 and 12

                       Month 6   Month 12                                                              
  -------------------- --------- ------------- ------------- ------- ----- ------------- ------------- -------
  Total                558       142 (25.4%)   416 (74.6%)           462   94 (20.3%)    368 (79.7%)   
  Recipient age                                              0.552                                     0.253
   \<40 years          183       47 (25.7%)    136 (74.3%)           156   25 (16.0%)    131 (84.0%)   
   40--54 years        211       58 (27.5%)    153 (72.5%)           179   41 (22.9%)    138 (77.1%)   
   ≥ 55 years          164       37 (22.6%)    127 (77.4%)           127   28 (22.0%)    99 (78.0%)    
  Gender                                                     0.965                                     0.747
   Male                382       97 (25.4%)    285 (74.6%)           323   67 (20.7%)    256 (79.3%)   
   Female              176       45 (25.6%)    131 (74.4%)           139   27 (19.4%)    112 (80.6%)   
  Race                                                       0.811                                     0.836
   White               468       120 (25.6%)   348 (74.4%)           395   81 (20.5%)    314 (79.5%)   
   Nonwhite            90        22 (24.4%)    68 (75.6%)            67    13 (19.4%)    54 (80.6%)    
  History of DM                                              0.760                                     0.704
   Yes                 87        21 (24.1%)    66 (75.9%)            68    15 (22.1%)    53 (77.9%)    
   No                  471       121 (25.7%)   350 (74.3%)           394   79 (20.1%)    315 (79.9%)   
  HLA mismatches                                             0.964                                     0.631
   0                   23        6 (26.1%)     17 (73.9%)            18    4 (22.2%)     14 (77.8%)    
   1--3                280       70 (25.0%)    210 (75.0%)           232   51 (22.0%)    181 (78.0%)   
   4--6                254       66 (26.0%)    188 (74.0%)           212   39 (18.4%)    173 (81.6%)   
  DGF                                                        0.883                                     0.429
   Yes                 96        25 (26.0%)    71 (74.0%)            76    18 (23.7%)    58 (76.3%)    
   No                  462       117 (25.3%)   345 (74.7%)           386   76 (19.7%)    310 (80.3%)   
  Donor status                                               0.095                                     0.051
   Living              185       39 (21.1%)    146 (78.9%)           152   23 (15.1%)    129 (84.9%)   
   Deceased            373       103 (27.6%)   270 (72.4%)           310   71 (22.9%)    239 (77.1%)   
  Dialysis                                                   0.738                                     0.820
   None                57        15 (26.3%)    42 (73.7%)            47    11 (23.4%)    36 (76.6%)    
   Hemodialysis        406       100 (24.6%)   306 (75.4%)           335   66 (19.7%)    269 (80.3%)   
   Peritoneal          95        27 (28.4%)    68 (71.6%)            80    17 (21.3%)    63 (78.8%)    
  CMV D/R                                                    0.857                                     0.661
   Neg./neg.           100       29 (29.0%)    71 (71.0%)            78    16 (20.5%)    62 (79.5%)    
   Neg./pos.           99        26 (26.3%)    73 (73.7%)            90    22 (24.4%)    68 (75.6%)    
   Pos./neg.           70        19 (27.1%)    51 (72.9%)            57    9 (15.8%)     48 (84.2%)    
   Pos./pos.           248       61 (24.6%)    187 (75.4%)           201   42 (20.9%)    159 (79.1%)   
  HCV D/R                                                    0.704                                     0.881
   Neg./neg.           543       138 (25.4%)   405 (74.6%)           450   91 (20.2%)    359 (79.8%)   
   Neg./pos.           11        3 (27.3%)     8 (72.7%)             10    2 (20.0%)     8 (80.0%)     
   Pos./neg.           0         0             0                     0     0             0             
   Pos./pos.           2         0             2 (100.0%)            1     0             1 (100.0%)    
  Cold ischemia time                                         0.168                                     0.062
   N                             141           411                         93            364           
   Median (h)                    14.3          12.0                        15.0          12.0          
   IQR                           (0, 35.5)     (0, 30.0)                   (0.3, 35.5)   (0, 29.2)     

###### 

Demographic and baseline determinants in patients with or without BK viruria at months 6 and 12

                       Month 6   Month 12                                                            
  -------------------- --------- ------------ ------------- ------- ----- ------------ ------------- -------
  Total                564       77 (13.7%)   487 (86.3%)           487   42 (8.6%)    445 (91.4%)   
  Recipient age                                             0.720                                    0.104
   \<40 years          186       23 (12.4%)   163 (87.6%)           161   10 (6.2%)    151 (93.8%)   
   40--54 years        212       32 (15.1%)   180 (84.9%)           185   14 (7.6%)    171 (92.4%)   
   ≥ 55 years          166       22 (13.3%)   144 (86.7%)           141   18 (12.8%)   123 (87.2%)   
  Gender                                                    0.937                                    0.052
   Male                386       53 (13.7%)   333 (86.3%)           342   35 (10.2%)   307 (89.8%)   
   Female              178       24 (13.5%)   154 (86.5%)           145   7 (4.8%)     138 (95.2%)   
  Race                                                      0.633                                    0.749
   White               472       63 (13.3%)   409 (86.7%)           409   36 (8.8%)    373 (91.2%)   
   Nonwhite            92        14 (15.2%)   78 (84.8%)            78    6 (7.7%)     72 (92.3%)    
                                                                                                     
  History of DM                                             0.732                                    0.230
   Yes                 88        11 (12.5%)   77 (87.5%)            78    4 (5.1%)     74 (94.9%)    
   No                  476       66 (13.9%)   410 (86.1%)           409   38 (9.3%)    371 (90.7%)   
  HLA mismatches                                            0.983                                    0.950
   0                   24        3 (12.5%)    21 (87.5%)            19    2 (10.5%)    17 (89.5%)    
   1--3                279       38 (13.6%)   241 (86.4%)           242   21 (8.7%)    221 (91.3%)   
   4--6                260       36 (13.8%)   224 (86.2%)           226   19 (8.4%)    207 (91.6%)   
  DGF                                                       0.292                                    0.718
   Yes                 97        10 (10.3%)   87 (89.7%)            83    8 (9.6%)     75 (90.4%)    
   No                  467       67 (14.3%)   400 (85.7%)           404   34 (8.4%)    370 (91.6%)   
  Donor status                                              0.918                                    0.192
   Living              186       25 (13.4%)   161 (86.6%)           160   10 (6.3%)    150 (93.8%)   
   Deceased            378       52 (13.8%)   326 (86.2%)           327   32 (9.8%)    295 (90.2%)   
  Dialysis                                                  0.286                                    0.993
   None                59        12 (20.3%)   47 (79.7%)            49    4 (8.2%)     45 (91.8%)    
   Hemodialysis        410       53 (12.9%)   357 (87.1%)           357   31 (8.7%)    326 (91.3%)   
   Peritoneal          95        12 (12.6%)   83 (87.4%)            81    7 (8.6%)     74 (91.4%)    
  CMV D/R                                                   0.535                                    0.232
   Neg./neg.           102       18 (17.6%)   84 (82.4%)            85    7 (8.2%)     78 (91.8%)    
   Neg./pos.           102       15 (14.7%)   87 (85.3%)            93    13 (14.0%)   80 (86.0%)    
   Pos./neg.           71        7 (9.9%)     64 (90.1%)            64    6 (9.4%)     58 (90.6%)    
   Pos./pos.           249       34 (13.7%)   215 (86.3%)           209   14 (6.7%)    195 (93.3%)   
  HCV D/R                                                   0.511                                    0.500
   Neg./neg.           547       73 (13.3%)   474 (86.7%)           474   40 (8.4%)    434 (91.6%)   
   Neg./pos.           13        3 (22.1%)    10 (76.9%)            11    2 (18.2%)    9 (81.8%)     
   Pos./neg.           0         0            0                     0     0            0             
   Pos./pos.           2         0            2 (100.0%)            1     0            1 (100.0%)    
                                                                                                     
  Cold ischemia time                                        0.845                                    0.965
   N                             76           482                         41           441           
   Median (h)                    12.0         12.2                        11.6         12.4          
   IQR                           (0, 35.5)    (0, 30.0)                   (0, 24.0)    (0, 35.5)     

N = total number of patients within category; n+ = number of patients with viruria; n− = number of patients without viruria; DM = diabetes mellitus; HLA = human leukocyte antigen; DGF = delayed graft function; CMV = cytomegalovirus serology; HCV = hepatitis C; D/R = donor / recipient; neg. = negative; pos. = positive.

p-values from chi-square tests, for cold ischemia time from Wilcoxon rank-sum tests.
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BKV viremia rates increased in both treatment arms over the first 3 months, but then diverged as patients in the CsA-arm had a lower rate of viremia compared to patients in the Tac-arm, both at month 6 (10.6% vs. 16.3%, p = 0.048) and at month 12 (4.8% vs. 12.1%, p = 0.004; [Figure 2](#fig02){ref-type="fig"}D). The on-treatment analysis revealed no significant differences in the incidence rates compared to the results presented above, e.g. BKV viremia at months 6 and 12 was 10.9% and 4.4% for the CsA- and 15.3% and 11.7% Tac-arm, respectively. The rate of high-level viremia of more than 10 000 copies/mL (4 log~10~) was lower in patients randomized to the CsA- than to Tac-arm at month 12 (2.2% vs. 9.4%, p\<0.001; [Figure 2](#fig02){ref-type="fig"}E). Moreover, median plasma BKV loads were 15-fold (1.2 log~10~/mL) lower in CsA-MPA than in Tac-MPA treated patients (p = 0.028; [Figure 2](#fig02){ref-type="fig"}F).

Other potential determinants of BKV replication were not significantly associated with BKV viruria or BKV viremia, but we noted a trend toward a higher rate of viremia at month 12 for male patients (male: 10.2%, female 4.8%, p = 0.052) and for higher rates of viruria and viremia in deceased donors ([Table 1A](#tbl1){ref-type="table"}).

Patients on CsA reached the C2 target range on average by day 15. Patients with viruria at month 6 had slightly lower CsA C2 values at month 3 (median 1053; interquartile range \[IQR\] 825, 1255) than those without viruria (median 1173; IQR 900, 1500; p = 0.041). Similarly, CsA C2 values at month 6 were lower in viruric patients (median 833, IQR 610, 1016) compared to nonviruric patients (median 934, IQR 697, 1204, p = 0.025). Patients on Tac reached the C0 target range on average by day 11. An association between Tac trough levels and the occurrence of viruria or viremia could not be identified (all p-values \>0.05). Since MPA exposure as measured by AUC was not determined in this study, MPA dosing was analyzed. MPA dosing decreased posttransplant in both treatment arms, but the mean dose of MPA was higher in CsA- than in Tac-treated patients at all time points in line with current clinical practice to accommodate lower exposure in CsA-treated patients (p-values \< 0.001; [Figure 3](#fig03){ref-type="fig"}). MPA-dosing was not different between patients with or without BKV viruria or viremia at month 6 (all p-values \> 0.10). To exclude undefined effects of the different CNI--MPA interaction, MPA-dosing was examined separately in patients of either treatment arm. There was no significant difference of MPA dosing in months 4--6 among Tac-MPA treated patients with or without viruria or viremia at month 6.
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Examining the role of steroids, we found no association with BKV viruria, but BKV viremia was significantly associated with a higher cumulative steroid exposure until month 1 having a median of 1470 mg (IQR 995 mg, 1808 mg) compared to 1250 mg (IQR 870 mg, 1655 mg) for patients without viremia (p = 0.031; [Table 2](#tbl3){ref-type="table"}). This difference persisted up to month 6 suggesting that corticosteroid exposure was an important modulator of the risk of BKV replication early posttransplant.

###### 

Cumulative dose of corticosteroids in patients with or without BK viruria and viremia at month 6

                        Viruria at month 6   Viremia at month 6                                         
  ---------- ---------- -------------------- -------------------- ------- -------------- -------------- -------
  ≤Month 1   Median     1241                 1274                 0.572   1470           1250           0.031
             (Q1, Q3)   (930, 1689)          (888, 1678)                  (995, 1808)    (870, 1655)    
  ≤Month 2   Median     1831                 1795                 0.409   1924           1770           0.017
             (Q1, Q3)   (1370, 2318)         (1330, 2205)                 (1476, 2409)   (1313, 2203)   
  ≤Month 3   Median     2161                 2112                 0.403   2315           2100           0.013
             (Q1, Q3)   (1625, 2791)         (1616, 2642)                 (1815, 3009)   (1606, 2643)   
  ≤Month 6   Median     3094                 2898                 0.404   3158           2897           0.021
             (Q1, Q3)   (2180, 3785)         (2160, 3593)                 (2549, 4217)   (2145, 3585)   

Cumulative dose in mg determined from transplantation up to end of the respective month.

Q1 = first quartile; Q3 = third quartile.

p-values from Wilcoxon rank-sum tests.

In the multivariate logistic regression model, BKV viruria was not significantly associated with any of the variables ([Table 3](#tbl4){ref-type="table"}). Investigating high-level viruria, however, randomization to CsA-MPA treatment significantly decreased the risk compared to Tac-MPA at month 6 (OR = 0.56, 95% CI 0.31, 0.99; p = 0.047) and month 12 (OR = 0.21, 95% CI 0.08, 0.57; p = 0.002). The cumulative steroid dose was still significant at month 6 (per 1 g higher: OR = 1.26), but not at month 12 ([Table 3](#tbl4){ref-type="table"}). For BKV viremia at month 6, CsA-MPA remained an independent factor decreasing risk compared to Tac-MPA (OR = 0.60, p = 0.044), while higher cumulative steroid dose increased the risk (per 1 g higher: OR = 1.19 per 1 g; p = 0.017). For BKV viremia at month 12, CsA-MPA was associated with decreased risk (OR of 0.33; p = 0.003). BKV viremia was independently associated with male gender (OR = 2.49; p = 0.038) and increasing age (OR = 1.41 per 10 years; p = 0.013; [Table 3](#tbl4){ref-type="table"}). For high-level viremia at month 12, CsA-MPA remained significant (OR = 0.19; p = 0.001), whereas age, gender or steroids were not.

###### 

Results from logistic regression analyses for occurrence of BK viruria and viremia at months 6 and 12 posttransplant dependent on the CNI type and other potential risk factors

                                                            Viruria (n = 558)   Viremia (n = 564)                                 
  --------------------------------------------------------- ------------------- ------------------- ------- ------ -------------- -------
  CNI (CsA vs. Tac)                                         0.85                (0.57, 1.24)        0.394   0.60   (0.36, 0.99)   0.044
  Age[a](#tf4-1){ref-type="table-fn"}                       0.99                (0.85, 1.16)        0.928   1.14   (0.94, 1.40)   0.187
  Gender (male vs. female)                                  1.00                (0.66, 1.51)        0.992   1.03   (0.61, 1.74)   0.920
  Race (white vs. nonwhite)                                 1.04                (0.60, 1.81)        0.892   0.69   (0.35, 1.34)   0.272
  History of DM (yes vs. no)                                1.10                (0.63, 1.92)        0.724   1.32   (0.64, 2.72)   0.449
  HLA mismatches (\>4 vs. \< = 4)                           0.88                (0.55, 1.40)        0.581   1.21   (0.66, 2.21)   0.544
  DGF (yes vs. no)                                          0.98                (0.59, 1.64)        0.947   1.62   (0.79, 3.32)   0.192
  Cumulative steroid dose[2](#tf4-2){ref-type="table-fn"}   1.09                (0.96, 1.24)        0.197   1.19   (1.03, 1.38)   0.017

                                                            Viruria (n = 462)   Viremia (n = 487)                                 
  --------------------------------------------------------- ------------------- ------------------- ------- ------ -------------- -------
  CNI (CsA vs. Tac)                                         0.64                (0.40, 1.03)        0.065   0.33   (0.16, 0.68)   0.003
  Age[1](#tf4-1){ref-type="table-fn"}                       1.19                (0.98, 1.44)        0.076   1.41   (1.07, 1.84)   0.013
  Gender (male vs. female)                                  1.12                (0.67, 1.86)        0.661   2.49   (1.05, 5.89)   0.038
  Race (white vs. nonwhite)                                 0.91                (0.46, 1.81)        0.791   0.75   (0.29, 1.96)   0.556
  History of DM (yes vs. no)                                1.00                (0.52, 1.92)        0.994   2.52   (0.83, 7.65)   0.103
  HLA mismatches (\>4 vs. \< = 4)                           1.16                (0.65, 2.05)        0.618   1.49   (0.64, 3.46)   0.349
  DGF (yes vs. no)                                          0.84                (0.46, 1.54)        0.579   0.80   (0.34, 1.86)   0.602
  Cumulative steroid dose[2](#tf4-2){ref-type="table-fn"}   1.08                (0.93, 1.25)        0.322   1.09   (0.88, 1.35)   0.424

Odds ratio represents an increment of 10 years.

Cumulative steroids dose up to month 3, odds ratio represents an increment of 1 g.

OR = odds ratio; CI = confidence interval; CNI = calcineurin inhibitor; CsA = cyclosporine; Tac = tacrolimus; DM = diabetes mellitus; HLA = human leukocyte antigen; DGF = delayed graft function defined as a decrease in serum creatinine ≤ 20% or the need for at least one dialysis in the first 3 days posttransplantation.

Discussion
==========

This prospective, randomized, multicenter study provides the largest systematic analysis of BKV viruria and viremia after kidney transplantation using a predefined protocol of immunosuppression. The results demonstrate that reactivation of BKV replication is common with BKV viruria reaching a cumulative incidence of 39.5% (95% CI 35.4%, 43.5%) by 12 months posttransplant. One-fourth of KT patients developed high-level viruria of \>7 log~10~ copies/mL, a molecular equivalent of urinary decoy cell shedding, as well as viremia, both biomarkers of an increasing risk of progression to PyVAN [@b9],[@b24]. Plasma BKV loads \>4 log~10~ copies/mL were observed in 16% of KT patients, thereby fulfilling the working definition of presumptive PyVAN for which judicious reduction of immunosuppression is currently recommended [@b15],[@b16]. The rates are in line with a smaller prospective study of 78 patients by Hirsch et al. reporting Kaplan--Meier estimates of high-level viruria (decoy cells) of 30% (95% CI 20--40%) and viremia of 13% (95% CI 5--21%) [@b9], as well as with results by Brennan et al. 2005 [@b11] and Ginveri et al. 2007 [@b13].

Randomizing more than 600 patients 1:1 to either CsA or Tac on a common backbone of basiliximab induction, MPA and prednisone provided an unprecedented large sample size associating CsA-MPA with a significantly lower rate of viremia than Tac-MPA, both at month 6 (10.6% vs. 16.3%, p = 0.048) and at month 12 (4.8% vs. 12.1%, p = 0.004). Furthermore, median plasma BKV loads were 10-fold higher at month 12 in Tac-MPA compared to CsA-MPA treated patients and high-level BKV viremia of \>4 log~10~ copies/mL was significantly more frequent. In the first 3 months, however, the rate of BKV replication did not significantly differ between patients randomized to CsA or Tac suggesting that differences between the CNIs did not play out early, but during the second half of the first year posttransplant, when most cases of PyVAN had been previously diagnosed [@b1],[@b4],[@b6]. Multivariate analysis confirmed the reduced risk of CsA-MPA treated patients for BKV viremia at months 6 and 12 compared to Tac-MPA, and identified higher steroid exposure in the first 3 months as an independent cofactor for high-level viruria and viremia. This association is of interest since it provides a rationale for the early onset of BKV replication, independent of the choice of CNI. Indeed, pulse-steroids had been identified as independent risk factor for high-level viruria (decoy cells), viremia and PyVAN [@b9]. Dadhania and colleagues reported that steroid maintenance therapy was associated with BKV replication [@b25]. The BKV-promoting effect of steroids likely is the result of both, activating BKV early gene expression via glucocorticoid response elements in the viral noncoding control region [@b26] and its immunosuppressive effect. This synergy of virus activation and immunity inactivation is also documented in the poor outcome of polyomavirus-associated nephropathy almost a decade ago when the disease was erroneously treated as acute cellular rejection [@b1],[@b2]. The results of our study further suggest that following protocol-driven corticosteroid dose tapering from month 3 onward, the choice CNI exerted a greater influence on BKV replication rates. Of note, male gender and older recipient age were identified as independent risk factors for BKV viremia at month 12. Both patient determinants have been reported previously as being associated with PyVAN in some single-center studies [@b4],[@b27] as well as in the large UNOS/OPTN registry analyses [@b7],[@b8].

Brennan et al. [@b11] randomized 200 KT patients in a ratio of 2:1 to either Tac or CsA that was combined with either azathioprine or MPA [@b11]. While the CNI *per se* was not found to influence the overall rates of BKV viruria and viremia in that study, there was a trend for an increased rate of sustained viremia in Tac- versus CsA-treated patients (p = 0.10). Similar to our results, BKV viruria was more frequent among Tac-MPA versus CsA-MPA treated patients (46% vs. 13%; p = 0.005). The rates of viremia in Tac-MPA versus CsA-MPA treated patients were similar to our study (13% vs. 4%), but without reaching statistical significance which may reflect their smaller sample size of 88 patients only in these comparator arms [@b11] compared to 629 patients reported here.

The difference between both Tac-MPA and CsA-MPA regarding BKV has previously been attributed to the potential influence of a higher overall immunosuppressive burden of Tac-containing regimens. In this study, CsA was targeted according C2 monitoring providing optimal exposure early posttransplant reaching median concentrations of 885 ng/mL at month 6, while tacrolimus was standard-dosed with predefined tapering reaching trough levels of 8 ng/mL at month 6. Under these conditions, the primary efficacy endpoints were found to be comparable including biopsy-proven acute rejection [@b22]. The significant association of BKV viremia with patients randomized to Tac may also be influenced by MPA exposure, but frequent and possibly more precise pharmacokinetic measurements were not performed [@b28]. On the other hand, representative time points posttransplant are not defined for comprehensive AUC measurements. This particularly concerns the question when to expect effects on BKV viremia, since pharmacokinetic measurements only provide data as a point prevalence that are not necessarily representative of concurrent, cumulative or subsequent effects. In our study, however, MPA dosing, decreased posttransplant and was, at all time points, significantly lower in patients randomized to Tac compared to CsA, in agreement with common routine practice to reduce differences in exposure ([Figure 3](#fig03){ref-type="fig"}). Of note, we found no difference in MPA doses between viruric or nonviruric, or between viremic and nonviremic patients within either CNI treatment group at month 6. Although screening was not yet widely recommended and practiced during the study period [@b15],[@b29], we cannot exclude that treatment for BKV viremia might have occurred and thereby shortened viremia duration in some patients. However, even with proactive reduction of immunosuppression, the median duration of BKV viremia is long ranging from 2.9 to 8.8 months [@b14],[@b30]. Given this long duration, we consider it unlikely that potential screening and treatment of some centers might have significantly changed the results.

Agent-specific mechanisms may also play a role in the different clinical adverse event profile of Tac and CsA as evidenced by changes in glucose or lipid metabolism [@b22]. Although Tac and CsA both inhibit the calcineurin phosphatase required for interleukin-2 expression in T-lymphocytes subsequent to T cell receptor activation, they have different molecular targets: CsA binds to cyclophilins while tacrolimus binds to FK-binding protein 12. Interestingly, *in vitro* studies indicate that CsA and MPA inhibit BKV replication [@b31]--[@b33], whereas Tac activates BKV replication via FK-binding protein 12 in primary human tubular epithelial cells [@b34]. The "net state of immunosuppression" coined by Rubin and Fishman [@b35] may be used to also integrate net effects on virus replication by different drugs as well as quantitative and qualitative differences of virus-specific T cell repertoire in the individual transplant recipients [@b36]. Clearly, at high doses of immunosuppressive drugs, BKV-inhibitory effects of CsA, mTOR inhibitors and MPA may not play out and immunosuppressive effects predominate. As dosing is lowered posttransplant, e.g. at 3 months onward, however, drug-specific differences may become apparent and BKV-activating effects as described for corticosteroids and Tac may increase the risk over drugs with BKV-inhibitory effects such as CsA, mTOR inhibitors and MPA, at an otherwise appropriate maintenance immunosuppression for a given patient--allograft combination. The role of differential direct activating and inhibiting viral effects of immunosuppressive drugs like tacrolimus versus cyclosporine, MPA and mTOR inhibitors are currently emerging, together with their differences in immunosuppressive action. The improved understanding direct drug mechanisms on infectious agents and the immune system will stimulate more specific clinical studies that allow to better evaluate the competing risks of rejection and infection in future personalized transplantation medicine.

In conclusion, CsA is associated with a significantly lower risk than Tac regarding BKV viremia at months 6 and 12 in *de novo* kidney transplant patients treated with basiliximab, MPA and steroids. Steroids appear as an independent risk factor for BKV viremia early posttransplant, whereas male gender and older age contribute later in the first year posttransplant, respectively. Together, these data support the hypothesis of a dynamic risk evolution across multiple factors including the choice of the CNI, thereby potentially influencing the screening after 6 months posttransplant and the management of patients at higher risk for BKV viremia and progression to nephropathy.
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